Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects

被引:35
作者
Chan, Clark
Yeo, Kwee P.
Pan, Alan X.
Lim, Maggie
Knadler, Mary P.
Small, David S.
机构
[1] Natl Univ Singapore, Ctr Clin Pharmacol, Lilly NUS, Clin Res Ctr, Singapore 117597, Singapore
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
CYP1A2; CYP2D6; duloxetine; pharmacokinetics; race;
D O I
10.1111/j.1365-2125.2006.02770.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To compare single- and multiple-dose duloxetine pharmacokinetics between healthy Japanese and Caucasians. Methods Twenty-four subjects of each race were given single oral doses of duloxetine (20, 40 and 60 mg) in a randomized, double-blind study. Another 20 subjects of each race received 20, 40 mg or placebo (2 : 2 : 1) twice-daily for 5 days. Results Following single doses, the mean duloxetine C-max and AUC were approximately 20% greater in Japanese. This difference could be explained by the 15% lower average body weight in Japanese. Similar results were observed following multiple dosing. Conclusion Duloxetine pharmacokinetics are not meaningfully different between Japanese and Caucasians.
引用
收藏
页码:310 / 314
页数:5
相关论文
共 6 条
[1]   A review and assessment of potential sources of ethnic differences in drug responsiveness [J].
Bjornsson, TD ;
Wagner, JA ;
Donahue, SR ;
Harper, D ;
Karim, A ;
Khouri, MS ;
Murphy, WR ;
Roman, K ;
Schneck, D ;
Sonnichsen, DS ;
Stalker, DJ ;
Wise, SD ;
Dombey, S ;
Loew, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (09) :943-967
[2]  
*E LILL PHARM, 2005, CYMB PACK INS
[3]  
Hasler Julia A., 1999, Molecular Aspects of Medicine, V20, P1, DOI 10.1016/S0098-2997(99)00005-9
[4]   Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects [J].
Lantz, RJ ;
Gillespie, TA ;
Rash, TJ ;
Kuo, F ;
Skinner, M ;
Kuan, HY ;
Knadler, MP .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) :1142-1150
[5]   Duloxetine: a new approach for treating stress urinary incontinence [J].
Moore, K .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2004, 86 :S53-S62
[6]   Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers [J].
Skinner, MH ;
Kuan, HY ;
Pan, A ;
Sathirakul, K ;
Knadler, MP ;
Gonzales, CR ;
Yeo, KP ;
Reddy, S ;
Lim, M ;
Ayan-Oshodi, M ;
Wise, SD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (03) :170-177